http://help4multiplesclerosis.com Your online resource center for Multiple Sclerosis Information Mon, 29 Nov 2010 10:15:03 +0000 en hourly 1 http://wordpress.org/?v=3.0.3 http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra/ http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra/#comments Tue, 08 Dec 2009 13:00:00 +0000 Multiple Sclerosis News From Medical News Today http://www.medicalnewstoday.com/articles/173289.php Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA)…

]]> http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra/feed/ 1 http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra-2/ http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra-2/#comments Tue, 08 Dec 2009 13:00:00 +0000 Multiple Sclerosis News From Medical News Today http://mnt.to/f/3vbx Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA)…

]]> http://help4multiplesclerosis.com/2009/12/08/biogen-idecs-oral-compound-bg-12-achieves-development-milestones-in-ms-and-ra-2/feed/ 0 http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases/ http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases/#comments Mon, 30 Nov 2009 08:00:00 +0000 Multiple Sclerosis News From Medical News Today http://www.medicalnewstoday.com/articles/172396.php Limitations in therapy induced by adverse effects due to unselective drug availability and therefore the use of potentially too high doses are a common problem. One prominent example for this dilemma are inflammatory diseases…

]]> http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases/feed/ 0 http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases-2/ http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases-2/#comments Mon, 30 Nov 2009 08:00:00 +0000 Multiple Sclerosis News From Medical News Today http://mnt.to/f/3tPj Limitations in therapy induced by adverse effects due to unselective drug availability and therefore the use of potentially too high doses are a common problem. One prominent example for this dilemma are inflammatory diseases…

]]> http://help4multiplesclerosis.com/2009/11/30/targeted-drug-delivery-approaches-by-nanoparticulate-carriers-in-the-therapy-of-inflammatory-diseases-2/feed/ 0 http://help4multiplesclerosis.com/2009/10/31/new-tool-to-accelerate-discovery-of-autoimmune-disease-mechanisms-and-therapies/ http://help4multiplesclerosis.com/2009/10/31/new-tool-to-accelerate-discovery-of-autoimmune-disease-mechanisms-and-therapies/#comments Sat, 31 Oct 2009 08:00:00 +0000 Multiple Sclerosis News From Medical News Today http://www.medicalnewstoday.com/articles/169329.php Currently, 5 – 8% of the U.S. population is afflicted with an autoimmune disease. Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways…

]]> http://help4multiplesclerosis.com/2009/10/31/new-tool-to-accelerate-discovery-of-autoimmune-disease-mechanisms-and-therapies/feed/ 0